To: Jimbo who wrote (18541 ) 11/13/1998 12:31:00 PM From: Jenna Respond to of 120523
FAQ's: JPMX,MALL,GNET,ORG MALL. been following for a while.. If you remember my post from yesterday I decided to 'discard' some preconceived notions about overbought oversold stocks.. Getting into ASYT yesterday andwatching CREE rebound so nicely.. well I decided today not to ignore MALL which has a remarkable chart. but did come up overbought. I missed all the move up in MALL until today. Today I finally joined in JPMX JPM Company JPMX Advest raised from Mkt Perform » Buy JPMX Janney Montgomery Accumulate » Buy the upgrade helped... It was in my database officially since Wednesday, after it came up on my scans. I liked the chart patterns and the fact that it closed pretty high on its intraday range yesterday. volume indicators and MACD were both bullish and the stock has been under accumulation. This is a 'severely beaten down' stock that disappointed earnings estimates by a lot. I would not even dare to think of what the future will bring for this one. It is a good trade for today as for how long? it's already up enough for a nice profit for 5 days. MALL is a whole different story. I like that company, been trading it about a year ago a lot. All this internet frenzy with AVCO and now NTPA.. This MALL could go on forever who knows. GNET: out at 50 considering reentering at 44 but decided not yet. ORG: I've had a nice profit from this twice before and yesterday it was up nicely. It's also an earnings play.. HemispheRxunfairly shorted - Business Week NEW YORK, Nov 12 (Reuters) - HemispheRx BioPharma Inc. (AMEX:HEB - news) and Organogenesis Inc. (AMEX:ORG - news) are being unfairly shorted, says a money manager in the November 23 issue of Business Week. Organogenesis plummeted from 37 in late April to 12-5/8, while Hemispherx fell from 12-1/2 on September 9 to 5 on September 25. On November 12, Organogenesis closed at 13-3/4, up 1-3/16, on the American Stock Exchange, and Hemispherx, also on the AMEX, closed at 8-3/16, down 1/8. Ray Dirks, founder of the ShortBusters Club, said in the article that Hemispherx is within two years of commercializing a new class of drugs for chronic viral disorders. Hemispherx's Ampligen has been called unsafe and defective by short sellers. ''They're wrong,'' says Dirks. ''If the drug was unsafe, the FDA wouldn't have permitted its use in this manner.'' The drug is in Phase III clinical trials, with patients paying the cost of the drugs. Hemispherx, he says, aims to develop an oral version of Ampligen, called Oragen, as well as other products for treating viral, immune deficiency, and other cancerous conditions.